DBV Technologies S.A. American Depositary Shares DBVT
i
Market dataready · fetched 2026-11-11T18:53:19.344Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T18:53:01.957973468Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T18:53:19.034467+00:00
DBV Technologies S.A. American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.96 | 737.5% | 54.9% | |||
| 25Δ | 8.60 | 697.8% | 51.3% | |||
| 30Δ | 9.24 | 658.1% | 47.6% | |||
| 35Δ | 9.87 | 618.4% | 44.0% | |||
| 40Δ | 10.51 | 578.7% | 40.3% | |||
| 45Δ | 11.15 | 539.0% | 36.7% | |||
| 50Δ | 17.20 | 533.7% | 67.1% | 11.79 | 499.3% | 33.0% |
| 55Δ | 15.74 | 468.1% | 54.8% | 12.43 | 459.6% | 29.4% |
| 60Δ | 14.28 | 402.5% | 42.4% | 13.07 | 419.9% | 25.7% |
| 65Δ | 12.83 | 336.9% | 30.1% | 13.70 | 380.2% | 22.0% |
| 70Δ | 11.37 | 271.3% | 17.7% | 14.34 | 340.5% | 18.4% |
| 75Δ | 14.98 | 300.8% | 14.7% | |||
| 80Δ | 15.62 | 261.1% | 11.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.96
- IV
- 737.5%
- B/E move
- 54.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.60
- IV
- 697.8%
- B/E move
- 51.3%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.24
- IV
- 658.1%
- B/E move
- 47.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.87
- IV
- 618.4%
- B/E move
- 44.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.51
- IV
- 578.7%
- B/E move
- 40.3%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.15
- IV
- 539.0%
- B/E move
- 36.7%
50Δ
- Pseudo strike
- 17.20
- IV
- 533.7%
- B/E move
- 67.1%
- Pseudo strike
- 11.79
- IV
- 499.3%
- B/E move
- 33.0%
55Δ
- Pseudo strike
- 15.74
- IV
- 468.1%
- B/E move
- 54.8%
- Pseudo strike
- 12.43
- IV
- 459.6%
- B/E move
- 29.4%
60Δ
- Pseudo strike
- 14.28
- IV
- 402.5%
- B/E move
- 42.4%
- Pseudo strike
- 13.07
- IV
- 419.9%
- B/E move
- 25.7%
65Δ
- Pseudo strike
- 12.83
- IV
- 336.9%
- B/E move
- 30.1%
- Pseudo strike
- 13.70
- IV
- 380.2%
- B/E move
- 22.0%
70Δ
- Pseudo strike
- 11.37
- IV
- 271.3%
- B/E move
- 17.7%
- Pseudo strike
- 14.34
- IV
- 340.5%
- B/E move
- 18.4%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.98
- IV
- 300.8%
- B/E move
- 14.7%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.62
- IV
- 261.1%
- B/E move
- 11.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 182.53% | |
| 178.11% |
Biotechnology
DFTX
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company is headquartered in New York, New…
More →DMAC
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis,…
More →DNA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide…
More →DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is…
More →DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and…
More →DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha…
More →